Multikinase inhibitors use in differentiated thyroid carcinoma
Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemi...
Gespeichert in:
Veröffentlicht in: | Biologics 2014-01, Vol.8, p.281 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 281 |
container_title | Biologics |
container_volume | 8 |
creator | Jasim, Sina Ozsari, Levent Habra, Mouhammed Amir |
description | Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinib |
doi_str_mv | 10.2147/BTT.S576l9 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A399886416</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A399886416</galeid><sourcerecordid>A399886416</sourcerecordid><originalsourceid>FETCH-LOGICAL-g676-1fb714a0b92c1f403ce94e77afeb8f6afbc38aa1a6192d69c9fcc7c83e73b1473</originalsourceid><addsrcrecordid>eNptTz1PwzAU9AASpbDwCyIxp9ix448FqVR8SUUMZK-eX-z2QeJIiTvw74mAgQHdcLrT3UnH2JXgq0ooc3PXNKu32ujOnbCFEMaUtTL1GTufpnfOdcWtXrDbl2OX6YMSTKGgdCBPeRin4vgti5ZiDGNImSCHtsiHz3GgtkAYkdLQwwU7jdBN4fKXl6x5uG82T-X29fF5s96We210KaI3QgH3rkIRFZcYnArGQAzeRg3Ro7QAArRwVasduoho0MpgpJ-vyCW7_pndQxd2lOKQR8CeJtytpXPWaiX0nFr9k5rRhp5wSCHS7P8pfAGb2Vjj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Multikinase inhibitors use in differentiated thyroid carcinoma</title><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jasim, Sina ; Ozsari, Levent ; Habra, Mouhammed Amir</creator><creatorcontrib>Jasim, Sina ; Ozsari, Levent ; Habra, Mouhammed Amir</creatorcontrib><description>Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinib</description><identifier>ISSN: 1177-5475</identifier><identifier>DOI: 10.2147/BTT.S576l9</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Drug therapy ; Enzyme inhibitors ; Health aspects ; Physiological aspects ; Protein kinases ; Thyroid cancer</subject><ispartof>Biologics, 2014-01, Vol.8, p.281</ispartof><rights>COPYRIGHT 2014 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Jasim, Sina</creatorcontrib><creatorcontrib>Ozsari, Levent</creatorcontrib><creatorcontrib>Habra, Mouhammed Amir</creatorcontrib><title>Multikinase inhibitors use in differentiated thyroid carcinoma</title><title>Biologics</title><description>Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinib</description><subject>Drug therapy</subject><subject>Enzyme inhibitors</subject><subject>Health aspects</subject><subject>Physiological aspects</subject><subject>Protein kinases</subject><subject>Thyroid cancer</subject><issn>1177-5475</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptTz1PwzAU9AASpbDwCyIxp9ix448FqVR8SUUMZK-eX-z2QeJIiTvw74mAgQHdcLrT3UnH2JXgq0ooc3PXNKu32ujOnbCFEMaUtTL1GTufpnfOdcWtXrDbl2OX6YMSTKGgdCBPeRin4vgti5ZiDGNImSCHtsiHz3GgtkAYkdLQwwU7jdBN4fKXl6x5uG82T-X29fF5s96We210KaI3QgH3rkIRFZcYnArGQAzeRg3Ro7QAArRwVasduoho0MpgpJ-vyCW7_pndQxd2lOKQR8CeJtytpXPWaiX0nFr9k5rRhp5wSCHS7P8pfAGb2Vjj</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Jasim, Sina</creator><creator>Ozsari, Levent</creator><creator>Habra, Mouhammed Amir</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20140101</creationdate><title>Multikinase inhibitors use in differentiated thyroid carcinoma</title><author>Jasim, Sina ; Ozsari, Levent ; Habra, Mouhammed Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g676-1fb714a0b92c1f403ce94e77afeb8f6afbc38aa1a6192d69c9fcc7c83e73b1473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Drug therapy</topic><topic>Enzyme inhibitors</topic><topic>Health aspects</topic><topic>Physiological aspects</topic><topic>Protein kinases</topic><topic>Thyroid cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jasim, Sina</creatorcontrib><creatorcontrib>Ozsari, Levent</creatorcontrib><creatorcontrib>Habra, Mouhammed Amir</creatorcontrib><jtitle>Biologics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jasim, Sina</au><au>Ozsari, Levent</au><au>Habra, Mouhammed Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multikinase inhibitors use in differentiated thyroid carcinoma</atitle><jtitle>Biologics</jtitle><date>2014-01-01</date><risdate>2014</risdate><volume>8</volume><spage>281</spage><pages>281-</pages><issn>1177-5475</issn><abstract>Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinib</abstract><pub>Dove Medical Press Limited</pub><doi>10.2147/BTT.S576l9</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1177-5475 |
ispartof | Biologics, 2014-01, Vol.8, p.281 |
issn | 1177-5475 |
language | eng |
recordid | cdi_gale_infotracmisc_A399886416 |
source | DOAJ Directory of Open Access Journals; Dove Press Free; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Drug therapy Enzyme inhibitors Health aspects Physiological aspects Protein kinases Thyroid cancer |
title | Multikinase inhibitors use in differentiated thyroid carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A11%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multikinase%20inhibitors%20use%20in%20differentiated%20thyroid%20carcinoma&rft.jtitle=Biologics&rft.au=Jasim,%20Sina&rft.date=2014-01-01&rft.volume=8&rft.spage=281&rft.pages=281-&rft.issn=1177-5475&rft_id=info:doi/10.2147/BTT.S576l9&rft_dat=%3Cgale%3EA399886416%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A399886416&rfr_iscdi=true |